Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 25

Sort by

Sort Order Select

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

Blood (2025) 146 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2025-5209

Published: 2025

Journal Articles

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Marie Sebert, Valeria Santini, Uwe Platzbecker, David Valcarcel, Uma Borate, Weishi Yuan, Stephanie Kapsalis, Lorene Simonot, Marissa Panzica, Prapti Patel, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 8254.

https://doi.org/10.1182/blood-2025-8254

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine

Courtney D. DiNardo, Dylan Marchione, Michael Heuser, Jianan Hui, Diego Gianolio, Scott Daigle, Sung Choe, Prapti Patel, Stephane De Botton, Hartmut Dohner

Blood (2023) 142 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2023-180549

Published: 2023

Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Blood (2022) 140 (Supplement 1): 1716–1719.

https://doi.org/10.1182/blood-2022-157326

Published: 2022

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Blood (2022) 140 (Supplement 1): 539–542.

https://doi.org/10.1182/blood-2022-159473

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Justin Watts, Michael Maris, Tara L. Lin, Prapti Patel, Yazan F. Madanat, Christopher R. Cogle, Gautam Borthakur, Dirk Huebner, Noor Khaskhely, Lynn Bonham, Monica Massaro, Daphne Taylor, Caroline Taromino, Alice S. Mims

Blood (2022) 140 (Supplement 1): 6204–6205.

https://doi.org/10.1182/blood-2022-167468

Published: 2022

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Benjamin Kroger, Yi Huang, Prapti Patel, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Jr., Farrukh T. Awan, Praveen Ramakrishnan, Kunal Verma, Russell Vittrup, Robert H. Collins, Madhuri Vusirikala, Yazan F. Madanat, Roni Tamari, Stephen S. Chung

Blood (2022) 140 (Supplement 1): 9833–9835.

https://doi.org/10.1182/blood-2022-171179

Published: 2022

Journal Articles

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Blood (2022) 139 (8): 1208–1221.

https://doi.org/10.1182/blood.2021011354

Published: 2022

Includes: Supplemental data

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Justin M Watts, Tara L. Lin, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2021-149337

Published: 2021

Journal Articles

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Tara L. Lin, Justin M Watts, Alice S. Mims, Prapti Patel, Paul J Shami, Elizabeth H. Cull, Christopher R. Cogle, Cynthia Lee, Fatih Uckun

Blood (2021) 138 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2021-149366

Published: 2021

Journal Articles

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 698.

https://doi.org/10.1182/blood-2021-144905

Published: 2021

Journal Articles

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Blood (2021) 138 (Supplement 1): 1276.

https://doi.org/10.1182/blood-2021-146507

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies

Suleyman Y Goksu, John Rolwes, Naveen Premnath, Prapti Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan, Ankit Kansagra, Larry D. Anderson, Jr., Farrukh T. Awan, Robert H. Collins, Stephen Chung, Yazan F. Madanat

Blood (2021) 138 (Supplement 1): 4134.

https://doi.org/10.1182/blood-2021-152930

Published: 2021

Journal Articles

Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort

Naveen Premnath, Stephen Chung, Suleyman Y Goksu, Prapti Patel, Ruth Ikpefan, John Rolwes, Mohak Pandey, Gurbakhash Kaur, Praveen Ramakrishnan, Ankit Kansagra, Farrukh T. Awan, Larry D. Anderson, Jr., Madhuri Vusirikala, Robert H. Collins, Michalis Agathocleous, Yazan F. Madanat

Blood (2021) 138 (Supplement 1): 1217.

https://doi.org/10.1182/blood-2021-149753

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of zefamenib in patients with relapsed/refractory acute leukemia

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Molecular Measurable Residual Disease in Patients with Newly Diagnosed m IDH1 Acute Myeloid Leukemia Treated with Ivosidenib + Azacitidine

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes

Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS

Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies

Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only